Add Company
Join Now

Vicore Pharma AB Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Pharma

Industry

Employee Data

  • Vicore Pharma AB has 44 Employees.(i)
  • Vicore Pharma AB grew their employee count by 22% last year.

Vicore Pharma AB's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M22116%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M91-10%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M16-6%$114.3MN/A
#8
$7.2M28-7%N/AN/A
#9
$13.7M51-9%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Vicore Pharma AB?

Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. Almee™ (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, reflecting its potential to have transformative impact. Using its unique expertise in ATRAG chemistry and biology, Vicore is further fueling its pipeline with several new therapies across additional potential indications. The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.

keywords:N/A

N/A

Total Funding

44

Number of Employees

N/A

Revenue (est)

22%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.1M44N/AN/A
#2
$9.5M44N/AN/A
#3
$4.9M44N/AN/A
#4
$5.8M44N/AN/A
#5
$8.9M44N/AN/A